News | Myriad Genetics

Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023

Jun 01, 2023 | Products | Corporate

Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics

May 31, 2023 | Corporate

Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer

May 24, 2023 | Products

Myriad Genetics Earns 2023 Great Place to Work Certification™

May 08, 2023 | Corporate

Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range

May 03, 2023 | Corporate | Financial

Myriad Genetics to Participate in BofA Securities Healthcare Conference

May 02, 2023 | Corporate

Myriad Genetics to Release First Quarter Financial Results on May 3, 2023

Apr 26, 2023 | Financial | Corporate

77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey

Apr 19, 2023 | Products

Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification

Apr 18, 2023 | Products

Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program

Apr 12, 2023 | Products | Corporate

Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States

Mar 02, 2023 | Products | Corporate

Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC

Mar 01, 2023 | Products

Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes

Feb 28, 2023 | Financial | Corporate

Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023

Feb 22, 2023 | Financial | Corporate

Myriad Genetics to Participate in Upcoming Healthcare Conferences

Feb 09, 2023 | Financial | Corporate

Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing

Feb 07, 2023 | Products

NASDAQ:

MYGN

$22.06

-5.84%

DAY HIGH

YEAR HIGH

DAY LOW

YEAR LOW

06/05/2023

NASDAQ:

MYGN

$22.06

-5.84%

News Releases

Select year

Categories

Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023

Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics

Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer

Myriad Genetics Earns 2023 Great Place to Work Certification™

Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range

Myriad Genetics to Participate in BofA Securities Healthcare Conference

Myriad Genetics to Release First Quarter Financial Results on May 3, 2023

77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey

Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification

Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program

Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States

Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC

Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes

Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023

Myriad Genetics to Participate in Upcoming Healthcare Conferences

Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing

Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities

Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference